Capital Markets

$18M will help CPH progress near-term revenue initiatives

Finfeed Archived Mar 26, 2021

Creso Pharma (ASX: CPH) has received firm commitments to raise $18M, a sum that significantly shores up its balance sheet. CPH will use the funds to progress a number of value accretive opportunities including Phase II and Phase III clinical trial initiatives with target acquisition company Halucenex Life Sciences Inc.

Capital markets must pivot, Tencent halted by Trump and … could Elixir Energy rise further?

Finfeed Archived Aug 14, 2020

President Trump suggested Tencent’s (HKG: 700) WeChat app poses a threat to US national security, and banned American companies from doing business with it.